Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Biofrontera Inc. Warrants (BFRIW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/26/2025: BFRIW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -6.25% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/26/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 19818 | Beta 0.31 | 52 Weeks Range 0.01 - 0.23 | Updated Date 03/27/2025 |
52 Weeks Range 0.01 - 0.23 | Updated Date 03/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.3 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -47.58% | Operating Margin (TTM) -13.63% |
Management Effectiveness
Return on Assets (TTM) -43% | Return on Equity (TTM) -384.98% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 6223910 |
Shares Outstanding - | Shares Floating 6223910 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Biofrontera Inc. Warrants
Company Overview
History and Background
Biofrontera Inc. is a biopharmaceutical company specializing in the development and commercialization of dermatological drugs. The warrants represent the right to purchase shares of Biofrontera Inc. common stock. Biofrontera AG (B8F:GR) was founded in 1997. Biofrontera Inc. was established as a US subsidiary focused on the US market. The warrants are derivative instruments tied to the underlying stock.
Core Business Areas
- Pharmaceuticals: Development and commercialization of prescription drugs for the treatment of skin conditions.
- Dermatology: Focus on products addressing dermatological issues, primarily actinic keratosis.
Leadership and Structure
Biofrontera Inc. is led by a management team focused on commercializing Biofrontera AG's products in the US market. The organizational structure is typical of a biopharmaceutical company, with departments for research and development, regulatory affairs, marketing, sales, and finance.
Top Products and Market Share
Key Offerings
- Ameluzu00ae: Prescription drug for photodynamic therapy in the treatment of actinic keratoses. Ameluz competes with topical creams like imiquimod (Aldara) and 5-fluorouracil, as well as cryotherapy. The overall market share for photodynamic therapy is growing but faces competition from alternative treatments.
- Xepiu2122: Topical treatment for impetigo, a bacterial skin infection. Competitors include mupirocin (Bactroban) and retapamulin (Altabax).
Market Dynamics
Industry Overview
The dermatology market is growing, driven by an aging population, increased awareness of skin conditions, and demand for cosmetic procedures. The market is competitive, with established pharmaceutical companies and emerging biotechs.
Positioning
Biofrontera Inc. is positioned as a specialty pharmaceutical company focused on dermatological indications. Its competitive advantage lies in its proprietary formulations and photodynamic therapy expertise.
Total Addressable Market (TAM)
The TAM for actinic keratosis and impetigo treatments is significant, estimated to be in the billions of dollars globally. Biofrontera Inc. aims to capture a portion of this market through its innovative products.
Upturn SWOT Analysis
Strengths
- Proprietary formulations
- Photodynamic therapy expertise
- Established distribution network in the US
- FDA-approved products
Weaknesses
- Reliance on a limited number of products
- High marketing and sales expenses
- Competition from established pharmaceutical companies
- Warrant price highly dependent on Biofrontera AG stock.
Opportunities
- Expansion into new dermatological indications
- Strategic partnerships and collaborations
- Geographic expansion
- Increasing awareness of actinic keratosis and photodynamic therapy
Threats
- Generic competition
- Changes in reimbursement policies
- Clinical trial failures
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- LEO Pharma (LEO)
- Galderma (private)
- Sun Pharma (SUNPHARMA.NS)
Competitive Landscape
Biofrontera faces stiff competition from larger pharmaceutical companies. Its advantages lie in its specialized focus and innovative products, while its disadvantages include limited resources and market reach. Market share data represents combined market share for actinic keratosis treatments and is highly variable
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth is linked to Biofrontera AG and the adoption of its products, particularly Ameluz, in the US market.
Future Projections: Future growth depends on successful commercialization of existing products, development of new products, and expansion into new markets.
Recent Initiatives: Recent initiatives include expanding the sales force, increasing marketing efforts, and pursuing regulatory approvals for new indications.
Summary
Biofrontera Inc. Warrants' value is closely tied to the success of Biofrontera AG and its products in the US. The company faces competition from larger pharmaceutical players but has the potential for growth through innovative products and expansion into new markets. Investors should closely monitor the performance of Biofrontera AG and the market dynamics of the dermatology industry. Risks to monitor include reliance on a limited product portfolio and strong competition.
Similar Companies
- LEO
- SUNPHARMA.NS
Sources and Disclaimers
Data Sources:
- Biofrontera AG Investor Relations
- Market Research Reports
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor. Market share data is approximate and based on publicly available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biofrontera Inc. Warrants
Exchange NASDAQ | Headquaters Woburn, MA, United States | ||
IPO Launch date 2021-10-29 | CEO, President & Chairman Dr. Hermann Luebbert Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 92 | Website https://www.biofrontera-us.com |
Full time employees 92 | Website https://www.biofrontera-us.com | ||
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.